Prescriptions for GLP-1 weight-loss medications dropped sharply in the first quarter of 2026 after California, New Hampshire, Pennsylvania, and South Carolina discontinued Medicaid coverage, according to a University of Pittsburgh study published in JAMA. Relative to 10 states that maintained coverage, quarterly prescriptions in the four states fell by roughly 84%.

Pennsylvania experienced the steepest decline at 95.5%, followed by New Hampshire at 88%, California at 75.2%, and South Carolina at 60.8%. Researchers estimate that between 175,500 and 526,600 fewer Medicaid enrollees filled these prescriptions after coverage was removed.

For low-income adults midway through treatment, the impact was immediate. Many were forced to choose between paying hundreds of dollars out of pocket each month, switching to an alternative, or discontinuing a medication their physicians had prescribed.

A Sharp Decline in Four States

All four states ended Medicaid coverage for GLP-1 drugs prescribed for weight loss on January 1, 2026, according to a News-Medical summary of the study. The medications include semaglutide, marketed as Wegovy, and tirzepatide, marketed as Zepbound.

In these four states, prescriptions per 100,000 Medicaid beneficiaries fell from 2,914 in the final quarter of 2025 to 421 in the first quarter of 2026. In the 10 states that retained coverage, the rate decreased only slightly, from 3,006 to 2,758.

The researchers found no statistically significant increase in prescriptions for GLP-1 drugs approved for diabetes, such as Ozempic, in the four states. This indicates that patients did not broadly switch to diabetes formulations of these medicines through Medicaid, though the study could not follow individual patients.

The drop followed years of rapid growth. Nationwide, quarterly Medicaid prescriptions for weight-loss GLP-1 drugs surged 5,858% from early 2022 to early 2026, compared with a 150% increase for GLP-1 drugs approved for diabetes. Since 2022, 17 state Medicaid programs have covered the drugs for weight loss at some point.

“These immediate declines corroborate what we saw clinically,” said lead author Dr. Bryant Shuey, an assistant professor of medicine at the University of Pittsburgh.

Budget Pressure Driving State Decisions

Federal Medicaid law does not require states to cover weight-loss drugs, although they must cover GLP-1 medications approved for diabetes, cardiovascular disease, and sleep apnea, according to a KFF analysis of Medicaid GLP-1 coverage. KFF also reports that nearly 4 in 10 adults with Medicaid have obesity.

California, New Hampshire, Pennsylvania, and South Carolina eliminated coverage because costs strained state budgets, Stateline reported. California projected that its annual cost for the drugs would have more than quadrupled over four years to nearly $800 million if Medi-Cal had continued covering them for weight loss, KFF Health News reported.

Other states have considered similar actions. Massachusetts and Rhode Island weighed dropping coverage this year, and North Carolina ended coverage in October 2025 before reinstating it in mid-December, Stateline reported. Michigan has narrowed eligibility. Overall, 13 state Medicaid programs covered GLP-1 drugs for obesity this year, down from 16 last year, according to Stateline.

Senior author Dr. Timothy Anderson, an associate professor of medicine at the University of Pittsburgh, said the decline was predictable. “It is not surprising that abruptly ending drug coverage creates major disruptions in care,” he said.

Study Evidence and Limitations

This was an observational study using fee-for-service and managed care Medicaid prescription data from all 50 states and Washington, D.C., from January 2022 through March 2026. It compared states that withdrew coverage with those that kept it. Because it tracked prescriptions rather than individuals, the exact number of patients affected is uncertain, which explains the wide estimate range.

The study could not measure what happened to patients’ health. It also could not capture people who paid cash or obtained the drugs through other means. The researchers did not isolate every change to state prior authorization rules, and other coverage changes may have contributed.

Patients Who Lost Coverage Mid-Treatment

The people most affected are low-income adults in the four states who were already taking a GLP-1 drug, particularly those with prediabetes, high blood pressure, or other weight-related conditions.

Stopping these drugs can have health consequences. Providers have warned that people typically regain weight after discontinuing GLP-1 medications, KFF Health News reported. Patients who have lost coverage should consult their clinician before stopping, so blood sugar, blood pressure, and weight can be monitored.

Options exist but vary, and none is automatic. Patients can ask whether they qualify for coverage under a different diagnosis, such as diabetes or cardiovascular disease. In California, Medi-Cal members can maintain GLP-1 coverage if they demonstrate medical necessity for a use other than weight loss. Novo Nordisk and Eli Lilly sell some GLP-1 drugs directly at reduced cash prices, though those prices can still reach hundreds of dollars per month. Patients should avoid unverified online sellers and compounded products from unlicensed sources.

Medicaid typically covers nutrition counseling and other weight-management services, though Shuey said finding covered options often requires more effort. Severe abdominal pain, persistent vomiting, or signs of dehydration while taking these drugs warrant prompt medical attention.

The researchers said future work will need to track what happened to patients’ weight and health after coverage ended, and whether some retained access through other covered uses, such as sleep apnea. MedicalDaily will report on that research.

Key Questions Answered

Which states dropped Medicaid coverage of GLP-1 weight-loss drugs? California, New Hampshire, Pennsylvania, and South Carolina, effective January 1, 2026.

How much did prescriptions fall? About 84% compared with 10 states that kept coverage. Pennsylvania had the largest drop, 95.5%.

How many people were affected? Researchers estimate 175,500 to 526,600 fewer beneficiaries filled prescriptions.

Why did states end coverage? Budget pressure. California projected annual costs approaching $800 million.

Is it risky to stop GLP-1 drugs suddenly? People typically regain weight after stopping. Talk with a clinician before stopping.

Does Medicaid still cover GLP-1 drugs for diabetes? Yes. States must cover them for diabetes and certain cardiovascular and sleep apnea uses.

Source link

Exit mobile version